Viewing Study NCT07410520


Ignite Creation Date: 2026-03-26 @ 3:20 PM
Ignite Modification Date: 2026-03-31 @ 11:48 AM
Study NCT ID: NCT07410520
Status: RECRUITING
Last Update Posted: 2026-02-13
First Post: 2026-02-08
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module